A review of the clinical and safety data on DROPSORDRY TM

Transcription

1 A review of the clinical and safety data on DROPSORDRY TM An effective ingredient to support normal urinary function* Distributed by By For more information: *claim on hold

2 URINARY INCONTINCENCE (UI) IN BRIEF What is UI? Urinary incontinence (UI) is a significant health problem defined as a loss of bladder control with symptoms ranging from mild leaking to uncontrollable wetting. This disorder directly affects a person s health and quality of life. UI affects more than million people worldwide. Incontinence is usually classified into two basic categories : What are the types of UI? Stress urinary incontinence (SUI) SUI is associated to involuntary leakage of urine caused by physical stress (coughing and heavy weight lifting). It develops due to an inadequate closure mechanism of the urethral sphincter which cannot resist increased intra-abdominal pressure. Urge urinary incontinence (UUI) Related to an urgent and irresistible desire to pass urine, which results in involuntary leakages of urine. UUI develops as a consequence of nervous dysregulation (overactive bladder (OAB)) Fig,. Prevalences of different types of UI by age and severity 3. Minassian. Urinary Incontinence in Women. Obstet Gynecol 8. How is UI treated? Treatments for incontinence range from simple behavioral training exercises to drugs and surgery. Usually drugs used include antibiotics, anticholinergic drugs, and estrogen which in most cases exhibit some undesirable side effects. For example, some studies shown estrogens may increase the risk of endometrial carcinoma, may cause elevated blood pressure, increase the risk of gallbladder disease and other undesirable effects 4. DROPSORDRY TM supplementation is an effective strategy for UI Luo, X., et al. International journal of clinical practice. 69. (5): ; Turgut. A, et al. Acta medica mediterranea 3.4 (4): 97-96; 3 V.A. Minassian, et al. Obstetrics & Gynecology., Part (8): 34-33; 4 Gibson, D A. et al. Endocrine-related cancer. (4): T3-T3;

3 Frequency Frequency Frequency Frequency CLINICAL STUDIES BENFEFITS OF DROPSORDRY SUPPLEMENTATION DURING MENOPAUSE AND PERI-MENOPAUSE IN EUROPEAN WOMEN Daily panty-liners Nocturnal urinary frequency,4 3,5,5,5 66%,5 69%,5 Urge urinary incontinence (UUI) 3 Stress urinary incontinence (SUI),8,5 46% 5%,6,4,,5 x5mg x5mg 96% of women refers a relief in urinary incontinence symptoms(n=8) 3 Marañón, J., et al. (6). Efficacy of Dropsordy supplementation on urinary incontinence in perimenopause. Gynecological Endocrinology, 3:sup, th World Congress of Gynecological Endocrinology. Firenze, Italy, March -5, 6. Marañón, J., et al. (6). Dropsordry decreases nighttime urinary episodes in women. Clinical study. Planta Med 6; 8 - PB35 3 Marañón, J., et al. (6). Clinical Efficacy and Tolerability of Dropsordry in Spanish Perimenopausal Women With Urgency Urinary Incontinence (uui). 8th International Conference on Obstetrics and Gynaecology. London, United Kingdom, February 5-6, 6. 4 Marañón, J., et al. (6). Dropsordry supplementation decreases nighttime urinary episodes in perimenopause with Urinary Incontinence. Clinical study. 4th EBCOG European congress of obstetrics and gynaecology. Torino, Italy, on May 9th th 6.

4 CLINICAL STUDIES ICIQ-SF QUESTIONNAIRE - Satisfaction with incontinence after 8 weeks 4% 3,8% Effectiveness 96% 96,% Improvement of quality of life 7,7% 7,7% Patients would continue with supplement 7,6% 84,6% 9,4% Relief in incontinence symptoms No side effects 7,7%,5% 7,7% 8,8% 9,3% Very satisfied Satisfied Dissatisfied YES NO Marañón, J., et al. (6). Clinical Efficacy and Tolerability of Dropsordry in Spanish Perimenopausal Women With Urgency Urinary Incontinence (uui). 8th International Conference on Obstetrics and Gynaecology. London, United Kingdom, February 5-6, 6. Marañón, J., et al. (6). Efficacy of Dropsordy supplementation on urinary incontinence in perimenopause. Gynecological Endocrinology, 3:sup, th World Congress of Gynecological Endocrinology. Firenze, Italy, March -5, 6.

5 DROPSORDRY IN BRIEF ABOUT - Proprietary blend of botanicals from SOLGEN soybean isoflavones and Cucurbita pepo. - Contains high levels of genistin & genistein isoflavones, the phytoestrogen that favorably contributes in menopause urinary incontinence - Genistein therapy regressed the degenerative changes associated at OAB symptoms - Proprietary clinical studies in European women -4 WHY - 73% reduction of urine leakages 3-46% reduction of Urge urinary incontinence episodes - 5% reduction of stress incontinence episodes (SUI) 3-69% reduction in nocturia 4,5-6% reduction in volume of nocturnal diuresis 4-66% of reduction in daily panty-liners 3 - GMP manufacturing (TRADICHEM INDUSTRIAL SERVICES) DOSAGE - x 5mg for the first 4 weeks. - x 5mg for the following weeks. 9% OF THE WOMEN SUBJECT OF THE STUDY REFERS AND OVERALL IMPROVEMENT IN THE QUALITY OF LIFE Turgut, A, et al. Acta Medica Mediterranea 3.4 (4): 97-96; Marañón, J., et al. 8th International Conference on Obstetrics and Gynaecology. London, United Kingdom, February 5-6, 6; 3 Marañón, J., et al. Gynecological Endocrinology, 3:sup, th World Congress of Gynecological Endocrinology. Firenze, Italy, March -5, 6; 4 Marañón, J., et al. Planta Med 6; 8 - PB35; 5 Marañón, J., et al. (6). 4th EBCOG European congress of obstetrics and gynaecology. Torino, Italy, on May 9th th 6.

6